784.97 USD
+1.26 (+0.16%)
786.5 USD
+1.53 (+0.19%)
Taking everything into account, REGN scores 6 out of 10 in our fundamental rating. REGN was compared to 530 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year REGN was profitable.
REGN had a positive operating cash flow in the past year.
REGN had positive earnings in each of the past 5 years.
Each year in the past 5 years REGN had a positive operating cash flow.
1.2 Ratios
REGN's Return On Assets of 11.40% is amongst the best of the industry. REGN outperforms 94.15% of its industry peers.
The Return On Equity of REGN (14.79%) is better than 94.72% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.69%, REGN belongs to the top of the industry, outperforming 94.15% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for REGN is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
Looking at the Profit Margin, with a value of 32.13%, REGN belongs to the top of the industry, outperforming 96.42% of the companies in the same industry.
REGN's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 27.61%, REGN belongs to the top of the industry, outperforming 96.42% of the companies in the same industry.
In the last couple of years the Operating Margin of REGN has declined.
With an excellent Gross Margin value of 86.28%, REGN belongs to the best of the industry, outperforming 88.87% of the companies in the same industry.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
The number of shares outstanding for REGN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, REGN has less shares outstanding
Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.67 indicates that REGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.67, REGN is in the better half of the industry, outperforming 77.74% of the companies in the same industry.
REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
REGN has a better Debt to FCF ratio (0.70) than 94.53% of its industry peers.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
REGN has a worse Debt to Equity ratio (0.09) than 63.40% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.67 |
ROIC/WACC1.02
WACC8.56%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.06, REGN is in line with its industry, outperforming 49.06% of the companies in the same industry.
REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio of 3.51. This is comparable to the rest of the industry: REGN outperforms 43.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
The Revenue has been growing slightly by 2.89% in the past year.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
REGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.38% yearly.
REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.63% yearly.
EPS Next Y-3.71%
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
EPS Next 5Y6.38%
Revenue Next Year0.28%
Revenue Next 2Y2.84%
Revenue Next 3Y5.1%
Revenue Next 5Y5.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.44, the valuation of REGN can be described as rather expensive.
Based on the Price/Earnings ratio, REGN is valued cheaply inside the industry as 95.09% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of REGN to the average of the S&P500 Index (26.57), we can say REGN is valued slightly cheaper.
With a Price/Forward Earnings ratio of 17.38, REGN is valued on the expensive side.
95.28% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 24.04. REGN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.44 | ||
| Fwd PE | 17.38 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaply inside the industry as 94.72% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaper than 95.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.26 | ||
| EV/EBITDA | 15.85 |
4.3 Compensation for Growth
The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.33
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
5. Dividend
5.1 Amount
REGN has a yearly dividend return of 0.47%, which is pretty low.
Compared to an average industry Dividend Yield of 1.02, REGN pays a better dividend. On top of this REGN pays more dividend than 98.30% of the companies listed in the same industry.
With a Dividend Yield of 0.47, REGN pays less dividend than the S&P500 average, which is at 1.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
5.2 History
REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
784.97
+1.26 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.98%
Inst Owner Change-0.48%
Ins Owners1.91%
Ins Owner Change3.09%
Market Cap82.50B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80
Price Target796.01 (1.41%)
Short Float %3.11%
Short Ratio2.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)6.45%
PT rev (3m)6.85%
EPS NQ rev (1m)1.08%
EPS NQ rev (3m)15.6%
EPS NY rev (1m)2.79%
EPS NY rev (3m)9.97%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)4.43%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)2.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.44 | ||
| Fwd PE | 17.38 | ||
| P/S | 5.79 | ||
| P/FCF | 21.26 | ||
| P/OCF | 16.27 | ||
| P/B | 2.66 | ||
| P/tB | 2.79 | ||
| EV/EBITDA | 15.85 |
EPS(TTM)45.01
EY5.73%
EPS(NY)45.16
Fwd EY5.75%
FCF(TTM)36.93
FCFY4.7%
OCF(TTM)48.25
OCFY6.15%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.33
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.67 |
F-Score5
WACC8.56%
ROIC/WACC1.02
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.71%
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.28%
Revenue Next 2Y2.84%
Revenue Next 3Y5.1%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-4.04%
EBIT Next 3Y6.12%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -3.71% in the next year.